EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials

J Andrew Berglund, Aaron Novack, Iva Ivanovska Holder, Soma Ray, Nicholas E Johnson

Journal of Neuromuscular Diseases · 2025

DOI: 10.1177/22143602251365101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, 2025. Verfasst von J Andrew Berglund und 4 weiteren Autor:innen. Beteiligte Einrichtung: The RNA Institute, University at Albany, SUNY, Albany, NY, USA. Hauptthemen laut MEDLINE: Myotonic Dystrophy, RNA Splicing, Clinical Trials as Topic, Alternative Splicing. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, NINDS NIH HHS, NCBDD CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myotonic dystrophy type 1 (DM1) is a slowly progressive, multi-systemic disorder with clinical phenotypes that vary by age of onset and severity of symptoms. It is the most common form of muscular dystrophy occurring in adults. Abnormal regulation of alternative splicing of pre-mRNA results from a repeat expansion mutation in the dystrophia myotonica protein kinase ( DMPK ) gene. The resulting spliceopathy is universal across affected individuals and clinical phenotypes and drives the clinical manifestations of DM1, which include a diverse array of signs and symptoms affecting most organ systems. There is currently no disease-modifying treatment for DM1. Heterogeneity in the developmental and degenerative features and patterns of DM1 complicates the stratification, powering, and execution of interventional clinical trials in a reasonable timeframe. The use of splicing change as a surrogate endpoint in DM1 evolved from the principle that the degree of DM1-affected exons relates to the level of functional muscleblind-like (MBNL) RNA-binding protein activity in muscle cell nuclei. Surrogate endpoints based on panels of mis-splicing events reflecting the underlying DM1 molecular mechanism are reasonably likely to predict clinical benefit in a timely fashion, thus enabling accelerated clinical development of therapies that address unmet needs in DM1. Natural history data from the DM1 population support a strong correlation between dysregulated splicing and muscle function and point to the utility of a composite splicing index as a surrogate endpoint to predict future functional benefit, particularly in clinical trials of reasonable duration. Ongoing and future clinical trials will hopefully address the validity of surrogate endpoints using changes in splicing and whether the correction of spliceopathy correlates with meaningful clinical outcome assessments in individuals with DM1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyRNA SplicingClinical Trials as TopicAlternative SplicingHumansBiomarkersMyotonin-Protein Kinase

Stichwörter der Autor:innen

DM1composite alternative splicing indexsurrogate biomarkertrinucleotide repeat expansion

Substanzen

BiomarkersMyotonin-Protein Kinase

Autor:innen und Institutionen

  • The RNA Institute, University at Albany, SUNY, Albany, NY, USA.
  • Dyne Therapeutics, Waltham, MA, USA.
  • Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
  • Center for Inherited Myology Research, Virginia Commonwealth University, Richmond, VA, USA.

Förderung

  • NCATS NIH HHS
  • NINDS NIH HHS
  • NCBDD CDC HHS
  • NIAID NIH HHS
  • FDA HHS

Zitieren

APA

Berglund, J. A., Novack, A., Ivanovska Holder, I., Ray, S., & Johnson, N. E. (2025). Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602251365101

Vancouver

Berglund JA, Novack A, Ivanovska Holder I, Ray S, Johnson NE. Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials. Journal of Neuromuscular Diseases. 2025. doi:10.1177/22143602251365101

BibTeX
@article{Berglund2025,
  author = {Berglund, J Andrew and Novack, Aaron and Ivanovska Holder, Iva and Ray, Soma and Johnson, Nicholas E},
  title = {Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials},
  journal = {Journal of Neuromuscular Diseases},
  year = {2025},
  doi = {10.1177/22143602251365101}
}
Kostenlos starten →